Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Beta-Hemolytic Nongroup A Streptococcal Pharyngitis in Children.

Frost HM, Fritsche TR, Hall MC.

J Pediatr. 2019 Mar;206:268-273.e1. doi: 10.1016/j.jpeds.2018.10.048. Epub 2018 Dec 6.

PMID:
30528760
2.

Infectious Mononucleosis and Lyme Disease as Confounding Diagnoses: A Report of 2 Cases.

Koester TM, Meece JK, Fritsche TR, Frost HM.

Clin Med Res. 2018 Dec;16(3-4):66-68. doi: 10.3121/cmr.2018.1419. Epub 2018 Aug 30.

3.

Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic.

Thomm AM, Schotthoefer AM, Dupuis AP 2nd, Kramer LD, Frost HM, Fritsche TR, Harrington YA, Knox KK, Kehl SC.

mSphere. 2018 Jan 10;3(1). pii: e00467-17. doi: 10.1128/mSphere.00467-17. eCollection 2018 Jan-Feb.

4.

The nasal microbiota of dairy farmers is more complex than oral microbiota, reflects occupational exposure, and provides competition for staphylococci.

Shukla SK, Ye Z, Sandberg S, Reyes I, Fritsche TR, Keifer M.

PLoS One. 2017 Aug 29;12(8):e0183898. doi: 10.1371/journal.pone.0183898. eCollection 2017.

5.

Serologic Evidence of Powassan Virus Infection in Patients with Suspected Lyme Disease1.

Frost HM, Schotthoefer AM, Thomm AM, Dupuis AP 2nd, Kehl SC, Kramer LD, Fritsche TR, Harrington YA, Knox KK.

Emerg Infect Dis. 2017 Aug;23(8):1384-1388. doi: 10.3201/eid2308.161971.

6.

Risk Factors for Severe Infection, Hospitalization, and Prolonged Antimicrobial Therapy in Patients with Babesiosis.

Mareedu N, Schotthoefer AM, Tompkins J, Hall MC, Fritsche TR, Frost HM.

Am J Trop Med Hyg. 2017 Oct;97(4):1218-1225. doi: 10.4269/ajtmh.17-0146. Epub 2017 Jul 19.

7.

Pro-inflammatory immune responses are associated with clinical signs and symptoms of human anaplasmosis.

Schotthoefer AM, Schrodi SJ, Meece JK, Fritsche TR, Shukla SK.

PLoS One. 2017 Jun 19;12(6):e0179655. doi: 10.1371/journal.pone.0179655. eCollection 2017.

8.

T2 Magnetic Resonance Assay-Based Direct Detection of Three Lyme Disease-Related Borrelia Species in Whole-Blood Samples.

Snyder JL, Giese H, Bandoski-Gralinski C, Townsend J, Jacobson BE, Shivers R, Schotthoefer AM, Fritsche TR, Green C, Callister SM, Branda JA, Lowery TJ.

J Clin Microbiol. 2017 Aug;55(8):2453-2461. doi: 10.1128/JCM.00510-17. Epub 2017 May 31.

9.

Serologic screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay.

Levin AE, Williamson PC, Bloch EM, Clifford J, Cyrus S, Shaz BH, Kessler D, Gorlin J, Erwin JL, Krueger NX, Williams GV, Penezina O, Telford SR 4th, Branda JA, Krause PJ, Wormser GP, Schotthoefer AM, Fritsche TR, Busch MP.

Transfusion. 2016 Jul;56(7):1866-74. doi: 10.1111/trf.13618. Epub 2016 May 25.

10.

Surveillance of Wisconsin Antibacterial Susceptibility Patterns.

Munson E, Block TK, Bowles EJ, Costello M, Dern R, Fritsche TR, Helgesen MA, Kropp JL, Podzorski RP, Siebers K, Simmons B, Smith MA, Spray F, Van TT, Warshauer DM.

WMJ. 2016 Feb;115(1):29-36.

11.

Human Infection with Ehrlichia muris-like Pathogen, United States, 2007-2013(1).

Johnson DK, Schiffman EK, Davis JP, Neitzel DF, Sloan LM, Nicholson WL, Fritsche TR, Steward CR, Ray JA, Miller TK, Feist MA, Uphoff TS, Franson JJ, Livermore AL, Deedon AK, Theel ES, Pritt BS.

Emerg Infect Dis. 2015 Oct;21(10):1794-9. doi: 10.3201/eid2110.150143.

12.

Appearances are Deceptive: Staphylococcus Superinfection of Clavicular Tuberculous Osteomyelitis.

Epperla N, Kattamanchi S, Fritsche TR.

Clin Med Res. 2015 Jun;13(2):85-8. doi: 10.3121/cmr.2014.1247. Epub 2014 Dec 8.

13.

A clinical, diagnostic, and ecologic perspective on human anaplasmosis in the Upper Midwest.

Schotthoefer AM, Meece JK, Fritsche TR.

WMJ. 2014 Jun;113(3):107-14; quiz 115.

14.

High diversity of plasmids harbouring blaCMY-2 among clinical Escherichia coli isolates from humans and companion animals in the upper Midwestern USA.

Bortolaia V, Hansen KH, Nielsen CA, Fritsche TR, Guardabassi L.

J Antimicrob Chemother. 2014 Jun;69(6):1492-6. doi: 10.1093/jac/dku011. Epub 2014 Feb 4.

PMID:
24500191
15.

Comparison of a real-time PCR method with serology and blood smear analysis for diagnosis of human anaplasmosis: importance of infection time course for optimal test utilization.

Schotthoefer AM, Meece JK, Ivacic LC, Bertz PD, Zhang K, Weiler T, Uphoff TS, Fritsche TR.

J Clin Microbiol. 2013 Jul;51(7):2147-53. doi: 10.1128/JCM.00347-13. Epub 2013 May 1.

16.

Preparation of corneal donor eyes comparing 1% versus 5% povidone-iodine.

Lindquist TD, Maxwell AJ, Miller TD, Win'E TL, Novicki T, Fritsche TR, Iliakis B, Montoya M.

Cornea. 2011 Mar;30(3):333-7. doi: 10.1097/ICO.0b013e3181eeb5d2.

PMID:
21045655
17.

Evidence of multiple virulence subtypes in nosocomial and community-associated MRSA genotypes in companion animals from the upper midwestern and northeastern United States.

Lin Y, Barker E, Kislow J, Kaldhone P, Stemper ME, Pantrangi M, Moore FM, Hall M, Fritsche TR, Novicki T, Foley SL, Shukla SK.

Clin Med Res. 2011 Mar;9(1):7-16. doi: 10.3121/cmr.2010.944. Epub 2010 Aug 25.

18.

Binaphthyl-based dicationic peptoids with therapeutic potential.

Bremner JB, Keller PA, Pyne SG, Boyle TP, Brkic Z, David DM, Garas A, Morgan J, Robertson M, Somphol K, Miller MH, Howe AS, Ambrose P, Bhavnani S, Fritsche TR, Biedenbach DJ, Jones RN, Buckheit RW Jr, Watson KM, Baylis D, Coates JA, Deadman J, Jeevarajah D, McCracken A, Rhodes DI.

Angew Chem Int Ed Engl. 2010;49(3):537-40. doi: 10.1002/anie.200904392. No abstract available.

PMID:
20014083
19.

Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).

Fritsche TR, Sader HS, Stillwell MG, Jones RN.

Diagn Microbiol Infect Dis. 2009 Apr;63(4):440-6. doi: 10.1016/j.diagmicrobio.2009.01.019.

PMID:
19302928
20.

Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.

Sader HS, Fritsche TR, Jones RN.

Antimicrob Agents Chemother. 2009 May;53(5):2171-5. doi: 10.1128/AAC.00129-09. Epub 2009 Mar 16.

21.

Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.

Fritsche TR, Biedenbach DJ, Jones RN.

Antimicrob Agents Chemother. 2009 Mar;53(3):1221-4. doi: 10.1128/AAC.01260-08. Epub 2008 Dec 29.

22.

Case report of Aurantimonas altamirensis bloodstream infection.

Mendes RE, Denys GA, Fritsche TR, Jones RN.

J Clin Microbiol. 2009 Feb;47(2):514-5. doi: 10.1128/JCM.02171-08. Epub 2008 Nov 26. No abstract available.

23.
24.

Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Pattanaik P, Bethel CR, Hujer AM, Hujer KM, Distler AM, Taracila M, Anderson VE, Fritsche TR, Jones RN, Pagadala SR, van den Akker F, Buynak JD, Bonomo RA.

J Biol Chem. 2009 Jan 9;284(2):945-53. doi: 10.1074/jbc.M806833200. Epub 2008 Oct 27.

25.

Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients.

Sader HS, Fritsche TR, Jones RN.

Int J Infect Dis. 2009 Mar;13(2):291-5. doi: 10.1016/j.ijid.2008.07.006. Epub 2008 Oct 19.

26.

Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates.

Jones RN, Fritsche TR, Sader HS.

Antimicrob Agents Chemother. 2008 Oct;52(10):3763-75. doi: 10.1128/AAC.00294-08. Epub 2008 Jun 23.

27.

Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine.

Mera R, Miller LA, Fritsche TR, Jones RN.

Microb Drug Resist. 2008 Jun;14(2):101-7. doi: 10.1089/mdr.2008.0782.

PMID:
18491947
29.

Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates.

Mendes RE, Fritsche TR, Sader HS, Jones RN.

Clin Infect Dis. 2008 Apr 15;46(8):1324-6. doi: 10.1086/533476. No abstract available.

PMID:
18444879
30.
31.

Pharmacokinetic and pharmacodynamic profile of ceftobiprole.

Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN.

Diagn Microbiol Infect Dis. 2008 May;61(1):96-102. doi: 10.1016/j.diagmicrobio.2008.02.013. Epub 2008 Apr 2. Review.

PMID:
18384996
32.

RmtD 16S RNA methylase in epidemiologically unrelated spm-1-producing Pseudomonas aeruginosa isolates from Brazil.

Castanheira M, Fritsche TR, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2008 Apr;52(4):1587-8; author reply 1588. doi: 10.1128/AAC.01502-07. No abstract available.

33.

Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.

Biedenbach DJ, Jones RN, Fritsche TR.

Diagn Microbiol Infect Dis. 2008 Jun;61(2):240-4. doi: 10.1016/j.diagmicrobio.2008.01.015. Epub 2008 Mar 19.

PMID:
18353594
34.

Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin America.

Fritsche TR, Castanheira M, Miller GH, Jones RN, Armstrong ES.

Antimicrob Agents Chemother. 2008 May;52(5):1843-5. doi: 10.1128/AAC.01477-07. Epub 2008 Mar 17.

36.

Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections.

Fritsche TR, Rhomberg PR, Sader HS, Jones RN.

J Antimicrob Chemother. 2008 May;61(5):1092-8. doi: 10.1093/jac/dkn074. Epub 2008 Feb 29.

PMID:
18310135
37.

In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.

Jones RN, Fritsche TR, Moet GJ.

Diagn Microbiol Infect Dis. 2008 May;61(1):76-9. doi: 10.1016/j.diagmicrobio.2007.12.010. Epub 2008 Jan 24. Erratum in: Diagn Microbiol Infect Dis. 2008 Jul;61(3):366-8.

PMID:
18221852
38.

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.

Sader HS, Fritsche TR, Jones RN.

Antimicrob Agents Chemother. 2008 Mar;52(3):1153-5. doi: 10.1128/AAC.01351-07. Epub 2008 Jan 7.

39.

Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.

Fritsche TR, Rhomberg PR, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2008 Mar;52(3):1187-9. doi: 10.1128/AAC.01475-07. Epub 2008 Jan 7.

40.

In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.

Fritsche TR, Rhomberg PR, Sader HS, Jones RN.

Diagn Microbiol Infect Dis. 2008 Apr;60(4):399-403. doi: 10.1016/j.diagmicrobio.2007.11.004. Epub 2008 Feb 21.

PMID:
18178361
42.

Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers.

Gales AC, Sader HS, Fritsche TR.

Diagn Microbiol Infect Dis. 2008 Apr;60(4):421-7. Epub 2008 Feb 20.

PMID:
18068934
43.

Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.

Jones RN, Sader HS, Fritsche TR, Janechek MJ.

Diagn Microbiol Infect Dis. 2007 Dec;59(4):467-72. Epub 2007 Nov 9.

PMID:
17997070
45.

WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.

Jones RN, Sader HS, Fritsche TR, Janechek MJ.

Diagn Microbiol Infect Dis. 2007 Oct 4. [Epub ahead of print]

PMID:
17919870
46.
47.

LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).

Jones RN, Fritsche TR, Sader HS, Ross JE.

Diagn Microbiol Infect Dis. 2007 Nov;59(3):309-17. Epub 2007 Aug 27.

PMID:
17720350
48.

Agar dilution and disk diffusion susceptibility testing of Campylobacter spp.

Fritsche TR, McDermott PF, Shryock TR, Walker RD, Morishita TY.

J Clin Microbiol. 2007 Aug;45(8):2758-9; author reply 2759. No abstract available.

49.

Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Rennie RP, Koeth L, Jones RN, Fritsche TR, Knapp CC, Killian SB, Goldstein BP.

J Clin Microbiol. 2007 Oct;45(10):3151-4. Epub 2007 Aug 1.

50.

Supplemental Content

Loading ...
Support Center